10309- ACT-18 A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN DIFFUSE GLIOMA WITH AN IDH1 MUTATION: UPDATED RESULTS
Timothy F Cloughesy, Ingo K Mellinghoff, Patrick Y Wen, Jennie W Taylor, Elizabeth A Maher, Isabel Arrillaga-Romany, Benjamin M Ellingson, Paria Mahboub-Johnson, Eric Baron, Islam Hassan, Lori Steelman, Jennifer L Clarke · 2024
Read 10309- ACT-18 A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN DIFFUSE GLIOMA WITH AN IDH1 MUTATION: UPDATED RESULTS by Timothy F Cloughesy, Ingo K Mellinghoff, Patrick Y Wen, Jennie W Taylor, Elizabeth A Maher, Isabel Arrillaga-Romany, Benjamin M Ellingson, Paria Mahboub-Johnson, Eric Baron, Islam Hassan, Lori Steelman, Jennifer L Clarke (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605638.txt.
Description
Timothy Cloughesy and co-authors report longer-term results from a trial of two targeted drugs in brain tumors carrying a gene mutation. The drugs, vorasidenib and ivosidenib, block a faulty enzyme produced by the mutated IDH1 gene in diffuse gliomas. Patients took one of the drugs, or none, for four weeks before surgery, then could continue afterward.
Forty-nine patients entered the trial, and forty-six continued on a drug after surgery. At the follow-up cutoff in late 2023, nearly half of the vorasidenib group were still on treatment, against a fifth of the ivosidenib group. Median time before the cancer grew again was forty-one months on one drug and thirty-nine on the other. Tumors shrank in forty-six percent of patients on vorasidenib and twenty-seven percent on ivosidenib. The update supports using drugs right after surgery for these slow-growing tumors.
Catalog record
| CREATOR | Timothy F Cloughesy, Ingo K Mellinghoff, Patrick Y Wen, Jennie W Taylor, Elizabeth A Maher, Isabel Arrillaga-Romany, Benjamin M Ellingson, Paria Mahboub-Johnson, Eric Baron, Islam Hassan, Lori Steelman, Jennifer L Clarke |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |